RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

MJFF has tiers of grants, ranging from those which fund target validation; to preclinical testing in various animal models; to preclinical testing intended to prepare drug for human testing (e.g. Prana's metal binding drug); to human testing (e.g. Ceregene's in vivo gene therapy trial, being funded in Phase II). At each step, the grants are fewer in number, but larger in size, because each step is more expensive.

IF the current Ampakine trial were to produce positive results, Cortex could then apply for the next step, and MJFF would decide which of those applicants looks most promising, and deserving of funding.

Bottom line: There's nothing guaranteed, but if an oral Ampakine were to look like it slows the course of the disease (which the Lilly compound did back in 2002) it would be competitive.

NeuroInvestment